Investor Presentaiton
Our strategic priorities
Research: Discovery
Services
Provide end-to-end therapeutic
discovery capabilities including
differentiating research technologies
and platforms, across many disciplines,
disease areas and therapeutic
modalities
Research: Dedicated
Centers
Continue to strengthen our existing
partnerships with Amgen, Bristol
Myers Squibb (BMS) and Baxter
through the dedicated centers which
provide: a strong foundation for future
planning; revenue visibility over the
medium to long term; and predictable
cash flows
Operational Excellence
Focus on customer delivery through
operational excellence
Syngene
Development and
Manufacturing Services -
Small Molecules
Leverage existing capabilities to offer
integrated Chemistry, Manufacturing,
and Controls (CMC) solutions
Secure US FDA and other major global
regulatory approvals for the small
molecule commercial scale
manufacturing facility as a platform to
attract a broader scope of projects
Development and
Manufacturing Services -
Large Molecules
Drive an integrated approach for
biologics development and
manufacturing to provide a one-stop-
shop capability from drug discovery to
commercial manufacturing for
biologics
Accelerate capacity build-up
People
Develop strong leaders and managers
while offering all employees career-
long learning opportunities
Environmental, Social and
Governance (ESG)
Committed to Science-based targets
and operate in a responsible and
sustainable manner.
Putting Science to Work
10View entire presentation